

3050 Spruce Street, St. Louis, MO 63103 USA
Tel: (800) 521-8956 (314) 771-5765 Fax: (800) 325-5052 (314) 771-5757
email: techservice@sial.com sigma-aldrich.com

# **Product Information**

Monoclonal Anti-Interleukin-6, clone 6708.11 produced in mouse, purified immunoglobulin

Catalog Number 17901

Synonym: Anti-IL-6

## **Product Description**

Monoclonal Anti-Interleukin-6 (IgG1 isotype) is purified from a mouse hybridoma. Recombinant, human IL-6 (rhIL-6) expressed in *E. coli* was used as immunogen. The antibody is purified by Protein A affinity chromatography.

Monoclonal Anti-IL-6 will neutralize the biological activity of rhIL-6. The antibody may also be used in immunoblotting and ELISA, By immunoblotting, the antibody shows no cross-reactivity with rmIL-6, rhIL-6 sR, rhOSM, rhLIF, rhIL-11, rhsgp130 and rhCNTF.

Interleukin 6 (IL-6) is a multifunctional 26 kDa protein originally discovered in the medium of RNA-stimulated fibroblastoid cells. Interleukin-6 appears to be directly involved in the responses that occur after infection and cellular injury, and it may prove to be as important as IL-1 and TNF- $\alpha$  in regulating the acute phase response.<sup>2,3</sup> IL-6 is reported to be produced by fibroblasts, activated T cells, activated monocytes or macrophages and endothelial cells. It acts upon a variety of cells including fibroblasts, myeloid progenitor cells, T cells, B cells and hepatocytes. Interleukin-6 induces multiple effects as indicated by its numerous synonyms: plasmacytoma growth factor (PCT-GF), interferon-β-2 (IFN-β<sub>2</sub>), monocyte derived human B cell growth factor, B cell stimulating factor (BSF-2), hepatocyte stimulating factor (HSF), and interleukin hybridoma/plasmacytoma-1 (IL-HP1). In addition, IL-6 appears to interact with IL-2 in the proliferation of T lymphocytes. 4 IL-6 potentiates the proliferative effect of IL-3 on multipotential hematopoietic progenitors.<sup>5</sup>

#### Reagent

Lyophilized from PBS without additives.

#### Reconstitution

To one vial of lyophilized powder, add 1 ml of 0.2  $\mu$ m-filtered PBS to produce a 0.5 mg/ml stock solution. If aseptic technique is used, no further filtration should be needed for use in cell culture environments.

## **Precautions and Disclaimer**

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

## Storage/Stability

Store at -20 °C.

Reconstituted product may be stored at 2-8 °C for up to one month. For prolonged storage, freeze in working aliquots at -20 °C. Avoid repeated freezing and thawing.

#### **Product Profile**

Anti-IL-6 is tested for its ability to neutralize the biological activity of rhIL-6 on the IL-6 dependent murine plasmacytoma cell line T1165.85.2.1. 
The ND $_{50}$  of the antibody is defined as the concentration of antibody resulting in a one-half maximal inhibition of bioactivity of rhIL-6 which is present at a concentration just high enough to elicit a maximum response. In this bioassay, rhIL-6 is incubated with various dilutions of the antibody for 1 hour at 37 °C in a 96-well microtiter plate. After the incubation, T1165.85.2.1 cells are added to the antigen-antibody mixture. The assay mixture, which contained a total volume of 0.2 ml with rhIL-6 at 2.5 ng/ml, is incubated at 37 °C for 48 hours in a humidified CO $_2$  incubator. Cell proliferation is measured with MTT.

## Results

Bioactivity:  $ND_{50} = 0.05 - 0.15 \,\mu g/ml$ 

Capture ELISA: 2-8 µg/ml capture antibody detects

0.6 pg/ml of rhlL-6.

Indirect

Immunoblotting: 1-2 μg/ml antibody detects rhIL-6 at

20 ng/lane under non-reducing and

reducing conditions.

### References

- 1. Billiau, A., Immunol. Today, 8, 84 (1987).
- 2. Gauldie, J., et al., *Proc. Natl. Acad. Sci. USA*, **84**, 7251 (1987).

- 3. Van Snick, J., Annu., Rev. Immunol., 8, 253 (1990).
- 4. Nordan, R. P., et al., *J. Immunol.*, **139**, 813 (1987).
- 5. Van Snick, J., et al., *Proc. Nat. Acad. Sci. USA*, **83**, 9679 (1986).
- 6. Nordan, R. P., and Potter, M., *Science*, **233**, 566 (1986).

TD,MR,PHC 05/14-1